Compare SUUN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUUN | ECOR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 50.0M |
| IPO Year | 2024 | 2018 |
| Metric | SUUN | ECOR |
|---|---|---|
| Price | $0.62 | $6.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 560.6K | 59.8K |
| Earning Date | 05-14-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | $112.68 | $34.03 |
| Revenue Next Year | $1.75 | $30.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $0.58 | $4.16 |
| 52 Week High | $2.79 | $8.55 |
| Indicator | SUUN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 50.73 |
| Support Level | N/A | $6.57 |
| Resistance Level | $0.90 | $6.61 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 20.45 | 56.27 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.